Who owns IMMIX BIOPHARMA INC?
- Ticker: IMMX
- CUSIP Number: 45258h106
Tip: Access positions for across all investors
Analyze quarterly positions in Immix Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Immix Biopharma stock
Who bought or sold IMMIX BIOPHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Henderson Group | 4.8M | $44M | 100% | Mar 2026 |
|
| Saturn V Capital Management | 3.0M | $16M | 100% | Dec 2025 |
|
| Eventide Asset Management | 2.5M | $13M | 100% | Dec 2025 |
|
| Marshall Wace | 2.0M | $10M | 3495% | Dec 2025 |
|
| Vanguard Capital Management | 1.8M | $16M | 100% | Mar 2026 |
|
| Millennium Management | 1.8M | $16M | 5% | Mar 2026 |
|
| Adage Capital Partners GP | 1.5M | $7.8M | 100% | Dec 2025 |
|
| Logos Global Management | 1.2M | $11M | 22% | Mar 2026 |
|
| Vanguard Group | 1.1M | $5.7M | 50% | Dec 2025 |
|
| Bleichroeder | 1.0M | $5.2M | 18% | Dec 2025 |
|
| Blue Owl Capital Holdings | 986k | $5.2M | 100% | Dec 2025 |
|
| Franklin Resources | 969k | $8.8M | -1% | Mar 2026 |
|
| Susquehanna International | 482k | $2.5M | 431% | Dec 2025 |
|
| BlackRock | 468k | $4.3M | 260% | Mar 2026 |
|
| Geode Capital Management | 463k | $4.2M | 88% | Mar 2026 |
|
| LGT Fund Management | 417k | $3.8M | 233% | Mar 2026 |
|
| Dr. Jeffrey R. Jay, M.D. | 350k | $3.2M | 100% | Mar 2026 |
|
| Institute For Wealth Management | 338k | $3.1M | 100% | Mar 2026 |
|
| Burkehill Global Management | 294k | $2.7M | 0% | Mar 2026 |
|
| Renaissance Technologies | 259k | $1.4M | 1103% | Dec 2025 |
|
| Vanguard Fiduciary Trust | 253k | $2.3M | 100% | Mar 2026 |
|
| KVP Capital Advisors | 230k | $2.1M | 0% | Mar 2026 |
|
| Sei Investments | 147k | $1.3M | 100% | Mar 2026 |
|
| Morgan Stanley | 140k | $1.3M | 10% | Mar 2026 |
|
| Eudaimonia Asset Management | 121k | $1.1M | 0% | Mar 2026 |
|
| J. Goldman & Co | 118k | $619k | 100% | Dec 2025 |
|
| Northern Trust | 101k | $526k | 13% | Dec 2025 |
|
| State Street Corporation | 97k | $509k | -2% | Dec 2025 |
|
| Goldman Sachs Group | 95k | $869k | -54% | Mar 2026 |
|
| Tocqueville Asset Management | 90k | $816k | 31% | Mar 2026 |
|
| Bank of New York Mellon | 84k | $762k | -15% | Mar 2026 |
|
| UBS Group | 77k | $700k | 31% | Mar 2026 |
|
| Virtu Financial | 74k | $386k | 100% | Dec 2025 |
|
| United Capital Financial Advisers | 71k | $644k | 0% | Mar 2026 |
|
| Hudson Bay Capital Management | 64k | $579k | 89% | Mar 2026 |
|
| Brevan Howard Capital Management | 58k | $524k | 100% | Mar 2026 |
|
| Palumbo Wealth Management | 55k | $503k | 100% | Mar 2026 |
|
| TD Asset Management | 53k | $485k | 100% | Mar 2026 |
|
| Qube Research & Technologies | 50k | $261k | 100% | Dec 2025 |
|
| Citadel Advisors | 47k | $430k | -37% | Mar 2026 |
|
| XTX Topco | 46k | $243k | 32% | Dec 2025 |
|
| Squarepoint Ops | 45k | $405k | 107% | Mar 2026 |
|
| Bank of America Corporation | 41k | $375k | 100% | Mar 2026 |
|
| Atlantic Trust | 40k | $209k | 300% | Dec 2025 |
|
| Jane Street | 35k | $320k | -79% | Mar 2026 |
|
| Camden Capital | 35k | $319k | 100% | Mar 2026 |
|
| Barclays | 35k | $183k | 100% | Dec 2025 |
|
| Velan Capital Investment Management | 35k | $183k | 0% | Dec 2025 |
|
| Private Advisor | 35k | $316k | 9% | Mar 2026 |
|
| Jump Financial | 34k | $177k | 100% | Dec 2025 |
|
| Imprint Wealth | 31k | $285k | 56% | Mar 2026 |
|
| Manufacturers Life Insurance Company | 29k | $264k | 100% | Mar 2026 |
|
| TritonPoint Partners | 25k | $223k | 100% | Mar 2026 |
|
| Concurrent Investment Advisors | 24k | $221k | -12% | Mar 2026 |
|
| Quadrature Capital | 22k | $116k | 100% | Dec 2025 |
|
| Fox Run Management | 21k | $178k | 100% | Mar 2026 |
|
| OMERS Administration Corporation | 20k | $186k | -73% | Mar 2026 |
|
| Vanguard Global Advisers | 20k | $180k | 100% | Mar 2026 |
|
| GSA Capital Partners | 18k | $162k | 100% | Mar 2026 |
|
| Wells Fargo & Company | 17k | $156k | 100% | Mar 2026 |
|
| Diametric Capital | 15k | $133k | 100% | Mar 2026 |
|
| Kera Capital Partners | 13k | $118k | 0% | Mar 2026 |
|
| Commonwealth Equity Services | 13k | $117k | 4% | Mar 2026 |
|
| Tower Research Capital | 12k | $64k | 100% | Dec 2025 |
|
| Mathes Company | 11k | $97k | 0% | Mar 2026 |
|
| Lighthouse Investment Partners | 10k | $52k | 100% | Dec 2025 |
|
| SBI Securities | 10k | $91k | 0% | Mar 2026 |
|
| ADAR1 Capital Management | 10k | $91k | -80% | Mar 2026 |
|
| Snowden Capital Advisors | 10k | $52k | 0% | Dec 2025 |
|
| Hanson McClain Advisors | 5.7k | $30k | 100% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 2.8k | $25k | 3% | Mar 2026 |
|
| Citigroup | 2.5k | $22k | 100% | Mar 2026 |
|
| CWM | 1.0k | $5.0k | 100% | Dec 2025 |
|
| Group One Trading | 879.00 | $8.0k | 100% | Mar 2026 |
|
| Royal Bank of Canada | 59.00 | $1.0k | 100% | Mar 2026 |
|
| Fortitude Family Office | 53.00 | $482.999600 | 100% | Mar 2026 |
|
| Aspect Partners | 9.00 | $81.999900 | 100% | Mar 2026 |
|
Who sold out of Immix Biopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Ameriprise Financial | Dec 2025 | 452k | $2.4M |
| Perceptive Advisors | Dec 2025 | 339k | $1.8M |
| Persistent Asset Partners | Dec 2025 | 32k | $166k |
| Balyasny Asset Management | Dec 2025 | 13k | $67k |
| Colony | Sep 2025 | 12k | $25k |